These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 37759475)

  • 21. Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells.
    Wang S; Allen N; Prakash TP; Liang XH; Crooke ST
    Nucleic Acid Ther; 2019 Oct; 29(5):245-255. PubMed ID: 31158063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs.
    Johannes L; Lucchino M
    Nucleic Acid Ther; 2018 Jun; 28(3):178-193. PubMed ID: 29883296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies in the design of endosomolytic agents for facilitating endosomal escape in nanoparticles.
    Ahmad A; Khan JM; Haque S
    Biochimie; 2019 May; 160():61-75. PubMed ID: 30797879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endosomal Escape of Antisense Oligonucleotides Internalized by Stabilin Receptors Is Regulated by Rab5C and EEA1 During Endosomal Maturation.
    Miller CM; Wan WB; Seth PP; Harris EN
    Nucleic Acid Ther; 2018 Apr; 28(2):86-96. PubMed ID: 29437530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System.
    Mendonça MCP; Kont A; Aburto MR; Cryan JF; O'Driscoll CM
    Mol Pharm; 2021 Apr; 18(4):1491-1506. PubMed ID: 33734715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies.
    Taniguchi H; Suzuki Y; Imai K; Adachi Y
    Cancer Sci; 2022 Sep; 113(9):2952-2961. PubMed ID: 35701833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is there a future for cell-penetrating peptides in oligonucleotide delivery?
    Lee SH; Castagner B; Leroux JC
    Eur J Pharm Biopharm; 2013 Sep; 85(1):5-11. PubMed ID: 23958313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: Advances, challenges, and future perspectives.
    Goto A; Yamamoto S; Iwasaki S
    Biopharm Drug Dispos; 2023 Feb; 44(1):26-47. PubMed ID: 36336817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers.
    Jin C; Ei-Sagheer AH; Li S; Vallis KA; Tan W; Brown T
    Angew Chem Int Ed Engl; 2022 Mar; 61(13):e202114016. PubMed ID: 34953094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Solid-phase synthesis of oligonucleotide conjugates useful for delivery and targeting of potential nucleic acid therapeutics.
    Lönnberg H
    Bioconjug Chem; 2009 Jun; 20(6):1065-94. PubMed ID: 19175328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reality check: lipid-oligonucleotide conjugates for therapeutic applications.
    Goodnow RA
    Expert Opin Drug Discov; 2023 Feb; 18(2):129-134. PubMed ID: 36546308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delivery of oligonucleotide-based therapeutics: challenges and opportunities.
    Hammond SM; Aartsma-Rus A; Alves S; Borgos SE; Buijsen RAM; Collin RWJ; Covello G; Denti MA; Desviat LR; Echevarría L; Foged C; Gaina G; Garanto A; Goyenvalle AT; Guzowska M; Holodnuka I; Jones DR; Krause S; Lehto T; Montolio M; Van Roon-Mom W; Arechavala-Gomeza V
    EMBO Mol Med; 2021 Apr; 13(4):e13243. PubMed ID: 33821570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent preclinical and clinical advances in oligonucleotide conjugates.
    Craig K; Abrams M; Amiji M
    Expert Opin Drug Deliv; 2018 Jun; 15(6):629-640. PubMed ID: 29727206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hsc70 Facilitates Mannose-6-Phosphate Receptor-Mediated Intracellular Trafficking and Enhances Endosomal Release of Phosphorothioate-Modified Antisense Oligonucleotides.
    Liang XH; Nichols JG; Hsu CW; Crooke ST
    Nucleic Acid Ther; 2021 Aug; 31(4):284-297. PubMed ID: 33567234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers.
    Jin C; Ei-Sagheer AH; Li S; Vallis KA; Tan W; Brown T
    Angew Chem Weinheim Bergstr Ger; 2022 Mar; 134(13):e202114016. PubMed ID: 38505643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs).
    Malecova B; Burke RS; Cochran M; Hood MD; Johns R; Kovach PR; Doppalapudi VR; Erdogan G; Arias JD; Darimont B; Miller CD; Huang H; Geall A; Younis HS; Levin AA
    Nucleic Acids Res; 2023 Jul; 51(12):5901-5910. PubMed ID: 37224533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrin targeted delivery of gene therapeutics.
    Juliano RL; Ming X; Nakagawa O; Xu R; Yoo H
    Theranostics; 2011 Mar; 1():211-9. PubMed ID: 21547161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.
    Juliano R; Alam MR; Dixit V; Kang H
    Nucleic Acids Res; 2008 Jul; 36(12):4158-71. PubMed ID: 18558618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemistry, structure and function of approved oligonucleotide therapeutics.
    Egli M; Manoharan M
    Nucleic Acids Res; 2023 Apr; 51(6):2529-2573. PubMed ID: 36881759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chloroquine and cytosolic galectins affect endosomal escape of antisense oligonucleotides after Stabilin-mediated endocytosis.
    Pandey E; Harris EN
    Mol Ther Nucleic Acids; 2023 Sep; 33():430-443. PubMed ID: 37575283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.